Inventiva SA
IVA3.450USD
+0.230+7.14%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
0.00Cap. mercado
--P/E TTM
Más Datos de Inventiva SA Compañía
Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Información de la empresa
Símbolo de cotizaciónIVA
Nombre de la empresaInventiva SA
Fecha de salida a bolsaFeb 15, 2017
Director ejecutivoMr. Frederic Cren
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscal- -
Dirección50 rue de Dijon
CiudadDAIX
Bolsa de valoresEuronext Paris
PaísFrance
Código postal21121
Teléfono33380447500
Sitio Webhttps://inventivapharma.com/
Símbolo de cotizaciónIVA
Fecha de salida a bolsaFeb 15, 2017
Director ejecutivoMr. Frederic Cren
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Lucy Lu, M.D.
Dr. Lucy Lu, M.D.
Independent Director
Independent Director
--
--
Mr. Heinz Maeusli
Mr. Heinz Maeusli
Independent Director
Independent Director
--
--
Dr. Mark Pruzanski, M.D.
Dr. Mark Pruzanski, M.D.
Chairman of the Board
Chairman of the Board
--
--
Ms. Nathalie Harroy
Ms. Nathalie Harroy
Head of Human Resources
Head of Human Resources
--
--
Mr. Frederic Cren
Mr. Frederic Cren
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Jean Volatier
Mr. Jean Volatier
Chief Financial Officer, Deputy General Manager
Chief Financial Officer, Deputy General Manager
--
--
Ms. Martine Zimmerman
Ms. Martine Zimmerman
Executive Vice President - Regulatory Affairs and Quality Assurance
Executive Vice President - Regulatory Affairs and Quality Assurance
--
--
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Annick Schwebig, M.D.
Dr. Annick Schwebig, M.D.
Independent Director
Independent Director
--
--
Dr. Jason Campagna, M.D., Ph.D.
Dr. Jason Campagna, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Lucy Lu, M.D.
Dr. Lucy Lu, M.D.
Independent Director
Independent Director
--
--
Mr. Heinz Maeusli
Mr. Heinz Maeusli
Independent Director
Independent Director
--
--
Dr. Mark Pruzanski, M.D.
Dr. Mark Pruzanski, M.D.
Chairman of the Board
Chairman of the Board
--
--
Ms. Nathalie Harroy
Ms. Nathalie Harroy
Head of Human Resources
Head of Human Resources
--
--
Mr. Frederic Cren
Mr. Frederic Cren
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Jean Volatier
Mr. Jean Volatier
Chief Financial Officer, Deputy General Manager
Chief Financial Officer, Deputy General Manager
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: jue., 17 de abr
Actualizado: jue., 17 de abr
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Yiheng Capital Management, L.P.
2.76%
New Enterprise Associates (NEA)
1.53%
BVF Partners L.P.
0.72%
Commonwealth Financial Network
0.06%
Wealth Enhancement Advisory Services, LLC
0.02%
Other
94.91%
Accionistas
Accionistas
Proporción
Yiheng Capital Management, L.P.
2.76%
New Enterprise Associates (NEA)
1.53%
BVF Partners L.P.
0.72%
Commonwealth Financial Network
0.06%
Wealth Enhancement Advisory Services, LLC
0.02%
Other
94.91%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
2.84%
Venture Capital
1.53%
Hedge Fund
0.72%
Other
94.91%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
19
4.87M
5.09%
-648.41K
2025Q1
21
4.87M
5.09%
-959.14K
2024Q4
21
5.45M
6.26%
-698.93K
2024Q3
20
4.86M
9.25%
-1.29M
2024Q2
21
4.85M
9.24%
-1.47M
2024Q1
22
4.85M
9.31%
-1.45M
2023Q4
19
4.86M
9.33%
-1.43M
2023Q3
22
4.86M
11.53%
-1.45M
2023Q2
24
4.83M
11.47%
-1.47M
2023Q1
26
5.13M
12.18%
-904.48K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Yiheng Capital Management, L.P.
2.64M
2.76%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
1.46M
1.53%
--
--
Mar 31, 2025
BVF Partners L.P.
686.04K
0.72%
--
--
May 07, 2025
Commonwealth Financial Network
54.49K
0.06%
+12.49K
+29.73%
Mar 31, 2025
Wealth Enhancement Advisory Services, LLC
10.71K
0.01%
+10.71K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
4.70K
0%
--
--
May 31, 2025
UBS Financial Services, Inc.
708.00
0%
-608.54K
-99.88%
Mar 31, 2025
BNP Paribas Securities Corp. North America
500.00
0%
-1.40K
-73.68%
Mar 31, 2025
Covestor, Ltd.
402.00
0%
--
--
Mar 31, 2025
Carson Wealth Management Group
--
0%
-100.00
-100.00%
Mar 31, 2024
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
